Geode Capital Management, LLC Acadia Pharmaceuticals Inc Transaction History

Geode Capital Management, LLC

$1.07 Trillion
Q1 2024

A detailed history of Geode Capital Management, LLC transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Geode Capital Management, LLC holds 2,793,237 shares of ACAD stock, worth $43.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,793,237

Previous 2,692,152 3.75%

Holding current value

$43.6 Million

Previous $84.3 Million 38.73%

% of portfolio

0.0%

Previous 0.01%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$17.79 - $30.86 $1.8 Million - $3.12 Million	101,085 Added 3.75%	2,793,237 $51.6 Million
Q4 2023 Feb 13, 2024	BUY	$20.78 - $31.77 $2.36 Million - $3.61 Million	113,770 Added 4.41%	2,692,152 $84.3 Million
Q3 2023 Nov 13, 2023	BUY	$20.84 - $33.47 $1.75 Million - $2.81 Million	84,044 Added 3.37%	2,578,382 $53.7 Million
Q2 2023 Aug 11, 2023	BUY	$17.8 - $25.65 $1.85 Million - $2.67 Million	104,071 Added 4.35%	2,494,338 $59.7 Million
Q1 2023 May 15, 2023	BUY	$16.32 - $20.92 $1.48 Million - $1.9 Million	90,768 Added 3.95%	2,390,267 $45 Million

Q4 2022 Feb 13, 2023	BUY	$14.2 - $18.63 $1.11 Million - $1.46 Million	78,348 Added 3.53%	2,299,499 $36.6 Million
Q3 2022 Nov 14, 2022	BUY	$14.11 - $18.27 $848,956 - $1.1 Million	60,167 Added 2.78%	2,221,151 $36.3 Million
Q2 2022 Aug 12, 2022	SELL	$13.01 - $27.22 $539,147 - $1.13 Million	-41,441 Reduced 1.88%	2,160,984 $30.4 Million
Q1 2022 May 13, 2022	BUY	$20.94 - $27.5 $801,436 - $1.05 Million	38,273 Added 1.77%	2,202,425 $53.3 Million
Q4 2021 Feb 11, 2022	BUY	$16.79 - $27.09 $2.4 Million - $3.87 Million	143,000 Added 7.08%	2,164,152 $50.5 Million
Q3 2021 Nov 12, 2021	SELL	$15.78 - $24.77 $854,455 - $1.34 Million	-54,148 Reduced 2.61%	2,021,152 $33.6 Million
Q2 2021 Aug 13, 2021	BUY	$19.4 - $27.42 $11.8 Million - $16.7 Million	608,790 Added 41.51%	2,075,300 $50.6 Million
Q1 2021 May 12, 2021	BUY	$25.02 - $54.99 $1.18 Million - $2.6 Million	47,298 Added 3.33%	1,466,510 $37.8 Million
Q4 2020 Feb 12, 2021	BUY	$41.04 - $56.79 $3.65 Million - $5.05 Million	88,896 Added 6.68%	1,419,212 $75.9 Million
Q3 2020 Nov 13, 2020	SELL	$36.42 - $57.0 $1.46 Million - $2.29 Million	-40,187 Reduced 2.93%	1,330,316 $54.9 Million
Q2 2020 Aug 13, 2020	SELL	$39.26 - $52.73 $14 Million - $18.9 Million	-357,567 Reduced 20.69%	1,370,503 $66.4 Million
Q1 2020 May 14, 2020	BUY	$31.65 - $46.87 $3.39 Million - $5.02 Million	107,011 Added 6.6%	1,728,070 $73 Million
Q4 2019 Feb 13, 2020	BUY	$36.21 - $51.4 $4.66 Million - $6.61 Million	128,565 Added 8.61%	1,621,059 $69.3 Million
Q3 2019 Nov 12, 2019	BUY	$22.22 - $44.01 $103,589 - $205,174	4,662 Added 0.31%	1,492,494 $53.7 Million
Q2 2019 Aug 14, 2019	BUY	$23.32 - $28.12 $1.54 Million - $1.86 Million	66,169 Added 4.65%	1,487,832 $39.8 Million
Q1 2019 May 14, 2019	BUY	$16.17 - $27.38 $2.86 Million - $4.84 Million	176,724 Added 14.2%	1,421,663 $38.2 Million
Q4 2018 Feb 13, 2019	BUY	$14.32 - $22.92 $2.54 Million - $4.07 Million	177,701 Added 16.65%	1,244,939 $20.1 Million
Q3 2018 Nov 13, 2018	BUY	$13.03 - $21.81 $815,743 - $1.37 Million	62,605 Added 6.23%	1,067,238 $22.2 Million
Q2 2018 Aug 14, 2018	BUY	$15.07 - $22.34 $1.49 Million - $2.21 Million	99,084 Added 10.94%	1,004,633 $15.3 Million
Q1 2018 May 15, 2018	BUY	$22.47 - $32.33 $799,302 - $1.15 Million	35,572 Added 4.09%	905,549 $20.3 Million
Q4 2017 Feb 13, 2018	BUY	$26.84 - $39.14 $666,893 - $972,511	24,847 Added 2.94%	869,977 $26.2 Million
Q3 2017 Nov 14, 2017	BUY	$29.49 - $38.37 $1.61 Million - $2.1 Million	54,720 Added 6.92%	845,130 $31.8 Million
Q2 2017 Aug 14, 2017	BUY	N/A	790,410	790,410 $22 Million

Others Institutions Holding ACAD

# of Institutions

299

Shares Held

158M

Call Options Held

1.88M

Put Options Held

688K

View Full List

About ACADIA PHARMACEUTICALS INC

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.52B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

More about ACAD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account

Geode Capital Management, LLC Acadia Pharmaceuticals Inc Transaction History